FN1 and Hepatic fibrosis: A similar effect of the BsAb is observed for primary hepatic stellate cells isolated from patients with liver fibrosis or primary lung fibroblasts isolated from patients with fibrotic lung disease (Supplementary Fig. S4), suggesting that this antibody may have the potential for broad use as a general antifibrotic agent to target activated fibroblasts that depend on FN and integrins α5β1/αvβ3 for matrix assembly.